⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CYCN News
Cyclerion Therapeutics, Inc. Common Stock
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
globenewswire.com
CYCN
Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus
globenewswire.com
ALMS
CYCN
BFRG
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
globenewswire.com
CYCN